Haselmeier acquired by Sulzer
Context
Sulzer has completed the acquisition of Haselmeier, integrating the drug delivery specialist into its Applicator Systems (APS) division. The transaction was structured to acquire 100% of the privately held Swiss-German company, allowing Sulzer to immediately scale its healthcare business and leverage Haselmeier’s significant portfolio of proprietary intellectual property.The strategic rationale for this acquisition is centered on technical synergy and market expansion. By combining Haselmeier’s competence in self-injection devices with Sulzer’s existing expertise in precision injection molding and liquid mixing, the group intends to accelerate the development of innovative and differentiated medical devices. This move allows Sulzer to pivot its APS division toward the high-growth pharmaceutical market, particularly in indications requiring frequent subcutaneous injections. The integration is expected to yield substantial cost synergies through the insourcing of manufacturing processes and the utilization of Sulzer’s global industrial infrastructure.
Haselmeier, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in the 20th century, Haselmeier is a leading Swiss-German developer and manufacturer of innovative drug delivery systems, specializing in subcutaneous self-injection devices. The company operates a high-value business model centered on proprietary intellectual property (IP), providing customized solutions such as injection pens for fast-growing medical indications including diabetes, reproductive health, growth disorders, and osteoporosis. Its value proposition lies in its end-to-end service offering, covering the entire product lifecycle from initial design, prototyping, and engineering to industrial-scale production in modern manufacturing facilities. Haselmeier’s strategy emphasizes being a reliable development partner for pharmaceutical companies, offering additional services such as lifecycle management, pharmaceutical packaging, and regulatory support. By focusing on patented platform technologies for injection devices, the company ensures the safe and precise self-administration of liquid drugs, catering to the increasing global demand for home-based healthcare and patient-centric delivery solutions.
Ent. Value
€100–350M
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Sulzer
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2021 | SULZER | NORDIC WATER | SWEDEN | Valves, Pumps & Taps |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2021 | SAGARD | NUTRISENS | FRANCE | Nutrition & Dietary Supplements |
| 11/2020 | NOVALPINA CAPITAL | LABORATOIRE X.O | FRANCE | Generics / Labs |
| 10/2020 | ARDIAN | H2 PHARMA | FRANCE | CDMO |
| 09/2020 | EQT PARTNERS | SCHÜLKE | GERMANY | Medical Consumables |
| 09/2020 | PATRICIA INDUSTRIES | ADVANCED INSTRUMENTS | UNITED STATES | Diagnostic Equipment |
| 09/2020 | NESTLE | IM HEALTHSCIENCE | UNITED STATES | Nutrition & Dietary Supplements |
| 09/2020 | PERMIRA | NEURAXPHARM | GERMANY | Generics / Labs |
| 06/2020 | AVISTA CAPITAL PARTNERS | VISION HEALTHCARE | BELGIUM | Nutrition & Dietary Supplements |
| 04/2020 | ROYAL DSM | GLYCOM | DENMARK | Nutrition & Dietary Supplements |
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
REFERENCES
Valuation range: EV €100–350M
Revenue range: €25–50M
EBITDA range: €5–25M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Haselmeier by Sulzer are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of Haselmeier by Sulzer valued, and what multiples were paid?
What were Haselmeier’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?